{"id":2111,"date":"2005-11-01T12:06:00","date_gmt":"2005-11-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/erhoehte-sterblichkeit-unter-der-behandlung-mit-salmeterol"},"modified":"2005-11-01T12:06:00","modified_gmt":"2005-11-01T11:06:00","slug":"erhoehte-sterblichkeit-unter-der-behandlung-mit-salmeterol","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/erhoehte-sterblichkeit-unter-der-behandlung-mit-salmeterol","title":{"rendered":"Erh\u00f6hte Sterblichkeit unter der Behandlung mit Salmeterol"},"content":{"rendered":"<p>Am 8. Oktober 2005 wurde im Lancet ein Brief der Public Citizen Health Research Group abgedruckt zum Thema \u201eMisleading data analyses in salmeterol (SMART) study\u201d (SMART = Salmeterol Multicenter Asthma Research Trial; 1). Es wird daran erinnert, dass GlaxoSmithKline (GSK) 1996 die SMART-Studie auf Veranlassung der Food and Drug Administration (FDA) begonnen hat, um dem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Am 8. Oktober 2005 wurde im Lancet ein Brief der Public Citizen Health Research Group abgedruckt zum Thema \u201eMisleading data analyses in salmeterol (SMART) study\u201d (SMART = Salmeterol Multicenter Asthma Research Trial; 1). Es wird daran erinnert, dass GlaxoSmithKline (GSK) 1996 die SMART-Studie auf Veranlassung der Food and Drug Administration (FDA) begonnen hat, um dem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[470,467,2797,3225],"class_list":["post-2111","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-asthma","tag-asthma-bronchiale","tag-salmeterol","tag-smart-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2111"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2111\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}